| Patient group | |||
---|---|---|---|---|
Characteristic | RF+ RA (n = 69) | RF- RA (n = 36) | SpA (n = 43) | UA (n = 90) |
Caucasian (%) | 77 | 85 | 94 | 82 |
Females (n) | 43 (61%) | 27 (73%) | 27 (63%) | 60 (67%) |
Age (years) | 47 ± 12* †| 43 ± 15 | 38 ± 11* | 41 ± 14†|
Symptom duration (weeks) | 32 ± 18 | 29 ± 26 | 45 ± 59 | 29 ± 19 |
Swollen joint count | 13 ± 9 | 14 ± 10 | 2 ± 2 | 3 ± 4 |
Total affected joint count | 19 ± 12 | 19 ± 11 | 5 ± 11 | 5 ± 7 |
ESR (mm/hour) | 44 ± 27 | 46 ± 33 | 36 ± 30 | 34 ± 29 |
CRP (mg/dl) | 1.8 ± 1.8 | 2.1 ± 2.2 | 1.9 ± 3.0 | 1.7 ± 2.2 |
Hemoglobin (mg/dl) | 13 ± 1.5 | 13 ± 1.7 | 13 ± 1.4 | 13 ± 1.6 |
Glucose (mg/dl) | 109 ± 53 | 99 ± 19 | 99 ± 35 | 97 ± 30 |
DMARD therapy (%) | 41 | 39 | 19 | 12 |
Prednisone therapy (%) | 36 | 44 | 26 | 11 |